KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Payables (2016 - 2025)

Rigel Pharmaceuticals has reported Payables over the past 16 years, most recently at $7.2 million for Q4 2025.

  • Quarterly results put Payables at $7.2 million for Q4 2025, up 115.36% from a year ago — trailing twelve months through Dec 2025 was $7.2 million (up 115.36% YoY), and the annual figure for FY2025 was $7.2 million, up 115.36%.
  • Payables for Q4 2025 was $7.2 million at Rigel Pharmaceuticals, up from $3.8 million in the prior quarter.
  • Over the last five years, Payables for RIGL hit a ceiling of $15.0 million in Q4 2022 and a floor of $1.7 million in Q2 2021.
  • Median Payables over the past 5 years was $4.9 million (2021), compared with a mean of $5.5 million.
  • Biggest five-year swings in Payables: soared 295.26% in 2022 and later crashed 57.37% in 2025.
  • Rigel Pharmaceuticals' Payables stood at $3.8 million in 2021, then soared by 295.26% to $15.0 million in 2022, then tumbled by 52.39% to $7.1 million in 2023, then tumbled by 53.25% to $3.3 million in 2024, then skyrocketed by 115.36% to $7.2 million in 2025.
  • The last three reported values for Payables were $7.2 million (Q4 2025), $3.8 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.